Peter Powchik - Regeneron Pharmaceuticals Senior Vice President - Clinical Development

REGN Stock  USD 966.30  2.75  0.29%   

President

Dr. Peter Powchik, M.D., is Senior Vice President Clinical Development of the Company. Dr. Powchik was employed at several pharmaceutical companies, serving as Senior Vice President and Chief Medical Officer of Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporationrationration, most recently as Vice President, US Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his M.D. from New York University School of Medicine. since 2006.
Age 59
Tenure 18 years
Address 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Phone914 847 7000
Webhttps://www.regeneron.com

Regeneron Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0849 % which means that it generated a profit of $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1626 %, meaning that it created $0.1626 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to 0.14. Also, Return On Assets is likely to grow to 0.13. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 28th of March 2024, Fixed Asset Turnover is likely to grow to 3.32, while Other Current Assets are likely to drop about 203.9 M.
The company currently holds 2.7 B in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Regeneron Pharmaceuticals has a current ratio of 5.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Regeneron Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Regeneron Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regeneron Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regeneron to invest in growth at high rates of return. When we think about Regeneron Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

PRESIDENT Age

Eilon AsculaiMediwound
N/A
Jacob ThaysenAgilent Technologies
49
Bruce CFAEquillium
58
Bruce SteelEquillium
50
Robert McMahonAgilent Technologies
55
Henrik AncherJensenAgilent Technologies
59
Patrick KaltenbachAgilent Technologies
53
Mark DoakAgilent Technologies
63
Dominique GrauAgilent Technologies
65
Rodney GonsalvesAgilent Technologies
58
Alicia RodriguezAgilent Technologies
N/A
Samraat RahaAgilent Technologies
51
Michael TangAgilent Technologies
50
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10915 people. Regeneron Pharmaceuticals (REGN) is traded on NASDAQ Exchange in USA. It is located in 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 and employs 13,450 people. Regeneron Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Regeneron Pharmaceuticals Leadership Team

Elected by the shareholders, the Regeneron Pharmaceuticals' board of directors comprises two types of representatives: Regeneron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regeneron. The board's role is to monitor Regeneron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Regeneron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regeneron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
Patrice Gilooly, Senior Operations
Christopher CPA, Head Finance
George Sing, Independent Director
Gerald Underwood, Senior Operations
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Ryan Crowe, Senior Analysis
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Andrew Murphy, Executive Research
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Bob McCowan, Senior Officer
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Regeneron Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regeneron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Transaction History
View history of all your transactions and understand their impact on performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.03)
Earnings Share
34.78
Revenue Per Share
122.935
Quarterly Revenue Growth
0.006
Return On Assets
0.0849
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.